지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.1
- 수록면
- 13 - 20 (8page)
이용수
초록· 키워드
오류제보하기
Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess fat builds up in the liver, often related to obesity and insulin resistance, which can lead to inflammation and scarring of the liver tissue. While efforts have been made to develop effective treatments for NAFLD, the need for pharmaceutical interventions remains unmet. Large clinical trials investigating the association between statin use and NAFLD are scarce, leading to contradictory results. Statins play a crucial role in cholesterol synthesis in the liver. Several studies have demonstrated that statins possess anti-inflammatory, anti-thrombotic, and anti-fibrotic properties. These properties make statins potentially useful in preventing the progression of NAFLD from simple steatosis to more severe forms like non-alcoholic steatohepatitis (NASH) and fibrosis. The results indicate that statin use is associated with a lower prevalence of NASH and fibrosis and may have a preventive effect on NAFLD.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Recent research trends and updates on nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2019 .01
-
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Clinical and Molecular Hepatology
2023 .02
-
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2020 .01
-
Risk factors in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Nonalcoholic fatty liver disease and non-liver comorbidities
Clinical and Molecular Hepatology
2023 .02
-
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Endocrinology and Metabolism
2020 .01
-
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Diabetes and Metabolism Journal
2019 .01
-
Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease
Journal of Obesity & Metabolic Syndrome
2022 .03
-
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
Diabetes and Metabolism Journal
2019 .01
-
Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index
Gut and Liver
2020 .01
-
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Clinical and Molecular Hepatology
2023 .04
-
Non-alcoholic fatty liver disease: Definition and subtypes
Clinical and Molecular Hepatology
2023 .02
-
Non-alcoholic fatty liver disease: the pathologist’s perspective
Clinical and Molecular Hepatology
2023 .02
-
The Immune Landscape in Nonalcoholic Steatohepatitis
Immune Network
2016 .06
-
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Clinical and Molecular Hepatology
2023 .02
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
Journal of Yeungnam Medical Science
2019 .01
-
The Association between Educational Attainment and the Risk of Nonalcoholic Fatty Liver Disease among Chinese Adults: Findings from the REACTION Study
Gut and Liver
2024 .07
-
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Clinical and Molecular Hepatology
2023 .02
-
Identification of high-risk subjects in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
최근 본 자료
댓글(0)
0